Remarkably, the percentage of CD4+ TEMs in DCM patients reached 29.82%, whereas it reached 1.81% in controls (p < 0.001), highlighting their crucial role in the DCM immune response and pathology. This evidence concerns the gene CD4 and familial dilated cardiomyopathy.